BBGBloomberg·3hBusiness
score+0.80
Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO
Original
Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO
“Strong positive framing with emphatic language ('Soars,' '44%') celebrating a successful fundraising milestone and market performance.”